October 28, 2016

Codman & Shurtleff, Inc.
Mr. Christopher Garete
Regulatory Affairs Specialist II
325 Paramount Drive
Raynham, Massachusetts 02767

Re: K162437
Trade/Device Name: Codman EDS3 CSF External Drainage System
Regulation Number: 21 CFR 882.5550
Regulation Name: Central Nervous System Fluid Shunt and Components
Regulatory Class: Class II
Product Code: JXG
Dated: September 28, 2016
Received: September 29, 2016

Dear Mr. Garete:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address 
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to 
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address 

Sincerely,

Carlos L. Peña -S

Carlos L. Peña, PhD, MS  
Director  
Division of Neurological and Physical Medicine Devices  
Office of Device Evaluation  
Center for Devices and Radiological Health

Enclosure
Indications for Use

Use of the Codman EDS3 CSF External Drainage System is indicated for draining cerebrospinal fluid (CSF) from the cerebral ventricles or the lumbar subarachnoid space as a means of reducing intracranial pressure and CSF volume when the insertion of a permanent, internal shunt is not indicated.

Type of Use (Select one or both, as applicable)

- [x] Prescription Use (Part 21 CFR 801 Subpart D)
- [ ] Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRASStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
510(k) Summary

I. Submitter
Codman & Shurtleff, Inc.
325 Paramount Drive
Raynham, MA 02767

Establishment Registration Number: 1226348

Primary Contact: Christopher Garete
Phone: (508) 977-3869
Fax: (508) 977-6979

Secondary Contact: Nancy MacDonald
Phone: (508) 828-3038
Fax: (508) 977-6979

Date of Preparation: September 26, 2016

II. Device

<table>
<thead>
<tr>
<th>Device Proprietary Name</th>
<th>Codman EDS3 CSF External Drainage System</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Name</td>
<td>External Drainage System</td>
</tr>
<tr>
<td>Classification Name</td>
<td>Central Nervous System Fluid Shunt and Components (21 CFR 882.5550)</td>
</tr>
<tr>
<td>Regulatory Classification</td>
<td>II</td>
</tr>
<tr>
<td>Product Code</td>
<td>JXG</td>
</tr>
</tbody>
</table>

III. Predicate Device

The predicate device for this submission is the Codman EDS3 CSF External Drainage System (K061568), which was cleared on September 29, 2006.

IV. Device Description

The Codman EDS3 CSF External Drainage System (Codman EDS3 System) is designed to collect cerebral spinal fluid (CSF) from the patient at a controlled rate based on differential pressure between the device and the patient. Collecting CSF from the patient is performed in efforts to reduce elevated intracranial pressure (ICP) post trauma.

The EDS3 device is comprised of four (4) main parts: ventricular catheter, patient drain line, base frame burette tube assembly and a collection bag.
The principle of operation of the proposed Codman EDS3 System is identical to the currently marketed Codman EDS3 System. The ventricular catheter is placed into one of the ventricles in the brain or in the subarachnoid space and is then connected to the patient drainage line. CSF flows from the brain through the patient line and enters into the 100 mL graduated burette tube assembly, where it is collected over a period of time to calculate a flow rate. The burette tube assembly can then be raised or lowered along the base frame, thereby adjusting the differential pressure to achieve the appropriate flow rate. Once the burette tube height is set, the collected CSF is then drained into the attached 700 ml collection bag.

The EDS3 System is a complete, disposable unit that is provided sterile and is available with or without a ventricular catheter.

V. Indications for Use

The Indications for Use statement of the proposed device remains similar to the predicate device. Two changes were made:

1) Anatomical locations of where CSF can be drained was added to the Indications and the statement
2) “fluids of similar characteristics” was removed to enhance clarity since fluid types falling into this category were not specified.

<table>
<thead>
<tr>
<th>Equivalence Comparison</th>
<th>Codman EDS3 CSF External Drainage System (Predicate: K061568)</th>
<th>Codman EDS3 CSF External Drainage System (Subject of This Submission)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indications for Use</td>
<td>Use of the Codman EDS3 CSF External Drainage System is indicated for draining cerebrospinal fluid (CSF) and other fluids of similar physical characteristics as a means of reducing intracranial pressure and CSF volume when the insertion of a permanent, internal shunt is not indicated.</td>
<td>Use of the Codman EDS3 CSF External Drainage System is indicated for draining cerebrospinal fluid (CSF) from the cerebral ventricles or the lumbar subarachnoid space as a means of reducing intracranial pressure and CSF volume when the insertion of a permanent, internal shunt is not indicated.</td>
</tr>
</tbody>
</table>
VI. Comparison to Predicate Device

The proposed Codman EDS3 CSF External Drainage System is identical to the currently marketed Codman EDS3 CSF External Drainage System (K061568) with the exception that this submission proposes use of adhesive Loctite 3924 instead of Loctite 3341 to bond the tubing lines to various components at several joints. The intended use, principle of operation, packaging, shelf life, sterilization method and SAL remain identical to the predicate device.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Codman EDS3 CSF External Drainage System (Predicate: K061568)</th>
<th>Codman EDS3 CSF External Drainage System (Subject of This Submission)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manufacturer</td>
<td>Codman &amp; Shurtleff, Inc.</td>
<td>Identical</td>
</tr>
<tr>
<td>Classification</td>
<td>Neurology</td>
<td>Identical</td>
</tr>
<tr>
<td>Classification Name</td>
<td>Central Nervous System Fluid Shunt and Components (21 CFR 882.5550)</td>
<td>Identical</td>
</tr>
<tr>
<td>Indications for Use</td>
<td>Use of the Codman EDS3 CSF External Drainage System is indicated for draining cerebrospinal fluid (CSF) and other fluids of similar physical characteristics as a means of reducing intracranial pressure and CSF volume when the insertion of a permanent, internal shunt is not indicated.</td>
<td>Use of the Codman EDS3 CSF External Drainage System is indicated for draining cerebrospinal fluid (CSF) from the cerebral ventricles or the lumbar subarachnoid space as a means of reducing intracranial pressure and CSF volume when the insertion of a permanent, internal shunt is not indicated.</td>
</tr>
<tr>
<td>Operating Principle</td>
<td>Drainage of CSF based on a differential pressure between the patient and the device.</td>
<td>Identical</td>
</tr>
<tr>
<td>Implant</td>
<td>No</td>
<td>Identical</td>
</tr>
<tr>
<td>Single Use Only</td>
<td>Yes</td>
<td>Identical</td>
</tr>
<tr>
<td>Shelf Life</td>
<td>3 years</td>
<td>Identical</td>
</tr>
<tr>
<td>Sterilization Method</td>
<td>EtO</td>
<td>Identical</td>
</tr>
<tr>
<td>Sterility Assurance Level (SAL)</td>
<td>$10^{-6}$</td>
<td>Identical</td>
</tr>
<tr>
<td>Non-Pyrogenic</td>
<td>Yes</td>
<td>Identical</td>
</tr>
<tr>
<td>Packaging</td>
<td>PETG Blister Tray with heat-sealed lid placed into a unit box</td>
<td>Identical</td>
</tr>
</tbody>
</table>
There were no changes made that affect the Codman EDS3 CSF External Drainage System indications for use, principle of operation, manufacturing process, clinical utility, packaging, shelf life, and sterilization. The only difference between the predicate and proposed device is the use of Loctite 3924 instead of Loctite 3341 as the adhesive for bonding the tubing at joints to improve the tensile strength and performance of the tubing line connections.

**Bench Testing:**
Visual Inspection, Functional Testing (Pressurized Leak and Flow Testing), Mechanical Testing (Tensile Strength and Torque Testing), Shelf Life, and Biocompatibility testing were performed to verify that the performance of the proposed device with adhesive Loctite 3924 is substantially equivalent to that of the current device, which uses adhesive Loctite 3341.

Please see the Summary of Testing Table below for Acceptance Criteria and testing results.

<table>
<thead>
<tr>
<th>Test</th>
<th>Test Method / Purpose</th>
<th>Acceptance Criteria</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visual Inspection</td>
<td>PIC-CL205063</td>
<td>Pass Visual Standards</td>
<td>Pass</td>
</tr>
<tr>
<td>Pressurized Leak and Flow</td>
<td>TM-TM095</td>
<td>Pass Leak and Flow Test</td>
<td>Pass</td>
</tr>
<tr>
<td>Shelf Life</td>
<td>Ensure the product remains functional after sterilization and 3 years of aging</td>
<td>Meet functional criteria after 2x EtO sterilization and 3 years of aging</td>
<td>Pass</td>
</tr>
<tr>
<td>Biocompatibility</td>
<td>ISO 10993</td>
<td>Pass Cytotoxicity Testing</td>
<td>Pass</td>
</tr>
</tbody>
</table>

Evaluate the Loctite
Animal Testing:
No animal studies were required as appropriate verification and validation of the design modifications were achieved based on the similarities of the proposed device to the predicate device, and from results of bench testing.

Clinical Testing:
No clinical studies were required as appropriate verification and validation of the design modifications were achieved based on the similarities of the proposed device to the predicate device, and from results of bench testing.

Conclusion:
Results from performance testing demonstrate that the modified device is suitable for its intended use and did not raise new issues of safety and effectiveness. Based on the indications for use, fundamental scientific technology and a comparison to the predicate device, the subject device Codman EDS3 CSF External Drainage System is substantially equivalent to the predicate device.